Visão geral da empresa
A pharmaceutical manufacturer with operations spanning North America, Europe, India, Russia, and other international markets, Dr. Reddy's Laboratories Limited functions as an integrated entity delivering solutions through its Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company operates within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which focuses on the development, production, and distribution of specialized and generic medicinal products essential for patient care. Dr. Reddy's Laboratories Limited demonstrates a substantial scale with a market capitalization of $11.05B and an annual revenue of $345.83B, supported by a workforce comprising 27811 employees. These valuation and revenue figures indicate a significant market presence, positioning the firm as a major player capable of influencing supply chains and pricing dynamics within the global pharmaceutical landscape. The size of the enterprise, reflected in its double-digit billions of dollars in revenue, suggests robust operational reach and the capacity to sustain extensive research and development initiatives alongside large-scale manufacturing capabilities.
Saúde financeira
The company reported a total revenue of $345.83B and generated net income of $56.59B, while achieving an EBITDA of $84.79B, highlighting the operational cash generation capabilities before interest, taxes, depreciation, and amortization. The substantial difference between the revenue figure and the net income reveals a cost structure where operating expenses, taxes, and interest charges consume a significant portion of the top line, resulting in a net income that is approximately 16.4% of total sales. Free cash flow stands at $13.47B, a metric that signifies the cash remaining after capital expenditures, providing the company with significant financial flexibility to fund operations, service debt, or pursue strategic acquisitions without immediate dilution. The gross margin is recorded at 55.2%, indicating that the company retains more than half of its sales revenue after covering the direct costs associated with producing its pharmaceutical goods. The operating margin and profit margin are both stated at 16.4%, suggesting that after accounting for overheads and other operating expenses, the company maintains a healthy profitability level relative to its sales volume. On the balance sheet, the company holds $82.59B in cash against total debt of $67.73B, resulting in a debt-to-equity ratio of 18.03, which indicates a leveraged position where debt obligations exceed equity capitalization. Despite the high leverage, the current ratio of 1.88 demonstrates that the company possesses sufficient current assets to cover its current liabilities nearly twice over, pointing to adequate short-term liquidity. Furthermore, the return on equity is 16.1% and the return on assets is 8.0%, metrics that reveal how effectively management utilizes shareholder equity and total assets to generate profit, with equity generating returns significantly higher than the overall asset base.
Avaliação de valorização
The trailing twelve-month P/E ratio is 18.14, while the forward P/E is projected at 23.73, a difference that implies the market expects earnings growth to be negative in the near term, as the forward multiple is higher than the trailing multiple despite the forward earnings estimate being lower. The price-to-book ratio stands at 2.77, indicating that the market values the company at a premium of roughly 177% over its book value, reflecting expectations of future growth or brand intangibles not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.03 and the EV/EBITDA of -0.01 suggest that traditional multiple comparisons are skewed by the reported financial figures, potentially due to the specific accounting treatments or debt levels affecting enterprise value calculations. The 52-week high is $16.17 and the 52-week low is $12.26, placing the current trading price within a defined range that reflects recent market volatility and investor sentiment regarding the healthcare sector. With a beta of 0.30, the stock exhibits low price volatility relative to the broader market, suggesting that its price movements are less sensitive to general market swings compared to the average stock. This low beta characteristic implies that the stock may serve as a defensive holding within a diversified portfolio, though it also suggests limited upside potential during broad market rallies. The disparity between the trailing and forward P/E ratios further underscores the disconnect between current earnings performance and future expectations, necessitating a careful review of the earnings growth drivers.
Growth & Income
Revenue growth over the last year is 4.4%, whereas earnings growth is -14.3%, indicating that earnings are declining faster than revenue, which implies rising costs or margin compression that is outpacing top-line expansion. As a dividend payer, the company offers a dividend yield of 0.7% with a payout ratio of 11.8%, a low ratio that suggests the dividend is highly sustainable even if earnings were to decline further. Given the negative earnings growth, the low payout ratio acts as a buffer, ensuring that the company does not pay out more than its earnings capacity. The overall growth and income profile is characterized by modest revenue expansion, significant earnings contraction, and a conservative approach to dividend distribution that prioritizes capital preservation over aggressive shareholder payouts.